MYC proto-oncogenes play a major role in various types of human tumors. The products of these genes are transcription factors that bind to speci®c sequences and activate the expression of target genes. Identifying these target genes and their downstream eectors is a crucial step in understanding and preventing MYC induced oncogenesis. Until now, most of the eorts to identify such genes were performed by analysing in vitro systems whose relevance to the malignant process in vivo remains unclear. We aimed at identifying genes that play a major role in the malignant process of MYC induced carcinogenesis. Thus, we analysed the expression pro®les of human MYC induced tumors and compared them to similar, non-MYC tumors. Moreover, we looked for the common characteristics of dierent types of MYC induced tumors. We identi®ed several genes, most of them involved in cell cycle regulation, that are over expressed in MYC induced lymphomas as well as MYC induced neuronal-like tumors. In order to determine whether MYC induced oncogenesis is similar in human and in the mouse model system, we analysed the expression of the identi®ed genes in cells derived from transgenic mice tumors. We also present the distribution of MYC putative binding sites in the regulatory sequences of the genes identi®ed in our analysis. This analysis pointed to two genes (E2F1 and TSC2) as candidates to be targets of Myc activity. We thus further analysed the expression of these genes in the tumor cell lines, and examined the plausibility that elements in their promoter bind the Myc protein. Our data points to several genes that may be involved in c-MYC and N-MYC induced tumors and to two genes that may be targets for MYC activity. Oncogene (2001) 20, 4984 ± 4994.
Introduction
The MYC family of oncoproteins (c-MYC, N-MYC, and L-MYC) are key players in the regulation of cell growth (for reviews see Evan and Littlewood, 1993; Facchini and Penn, 1998; Obaya et al., 1999; Schmidt, 1999) , in dierentiation processes (Freytag, 1988; Gandarillas and Watt, 1997 ; for review see Marcu et al., 1992) and in some circumstances in apoptosis ; for reviews see Dang et al., 1997; Prendergast, 1999) . All three proto-oncogenes are involved in a variety of human malignancies where they play a major role (for reviews see Cole, 1986; Marcu et al., 1992; Nesbit et al., 1999) .
The c-MYC oncogene is involved in a wide spectrum of human tumors where it is activated through several possible mechanisms. In Burkitt's lymphoma (BL), the hallmark of c-MYC oncogenesis, the c-MYC oncogene is expressed in a constitutive manner due to the erroneous regulation of an immunoglobin promoter brought to proximity by a chromosomal translocation (Leder et al., 1983; Bishop, 1987) . The c-MYC gene is also ampli®ed in various human tumors and is overexpressed in almost a third of breast cancers (Escot et al., 1986; Guerin et al., 1988) . The N-MYC oncogene is involved in a more restricted set of malignancies, predominantly in neuroblastomas (NB) and related tumors (Schwab et al., 1983; Brodeur et al., 1984) . L-MYC is a key player in the formation of small cell lung carcinomas (Nau et al., 1985) . Both N-MYC and L-MYC genes are ampli®ed in tumors, sometimes up to several hundred copies, resulting in the over-expression of the proteins (Schwab et al., 1983; Brodeur et al., 1984; Nau et al., 1985) .
MYC genes maintain distinct expression patterns during embryonic development (Zimmerman et al., 1986) . A null mutation in either c-MYC or N-MYC is embryonically lethal (Charron et al., 1992; Stanton et al., 1992; . Thus, it has been suggested that dierent MYC proteins may act as highly redundant proteins diering from each other by a distinct expression pattern. It has been recently shown that when the c-MYC gene was substituted by the N-MYC gene in a`knock in' experiment, the mice were normal (Malynn et al., 2000) . This may suggest that indeed, the c-MYC and N-MYC genes are functionally redundant genes that are involved in dierent processes in the cell due to their speci®c regulation.
MYC genes encode a family of basic helix ± loop ± helix leucin zipper (bHLH-LZ) proteins. MYC proteins can act as transcription factors when creating a heterodimer with the ubiquitously expressed protein MAX (Prendergast and Zi, 1992) . The MYC-MAX complex activates transcription by binding DNA, mainly to a speci®c E-box hexamer, CACGTG (Blackwell et al., 1990) . c-MYC has also been reported to repress transcription mediated by initiator elements although the mechanism involved is still unclear (Claassen and Hann, 1999) .
Deciphering the role of the MYC genes in human cancer is of great medical importance. As MYC genes are involved in many and sometimes contradicting processes, it seems that their action is mediated via speci®c target genes that may be activated dierentially. In light of this, the ®rst step in understanding MYC induced oncogenesis would be to identify and characterize MYC targets and downstream eectors. Several c-MYC targets have been suggested in recent years and they gave some indication of the processes that are regulated by MYC (Grandori and Eisenman, 1997; Facchini and Penn, 1998; Dang, 1999) . Yet, there is a need for a comprehensive analysis of MYC induced processes and genes.
Though identifying genetic targets for c-MYC has proven to be dicult, several approaches have been undertaken. In recent years, an in vitro approach, by using the MYC-ER inducible construct, has been proli®c (Grandori and Eisenman, 1997). Lately, an expression analysis of cells expressing the MYC-ER construct performed by oligonucleotide microarray has identi®ed several new putative target genes (Coller et al., 2000; O'Hagan et al., 2000) . However it is important to emphasize that the relevance of the target genes identi®ed using this in vitro system to the malignant processes induced by MYC genes is still unclear. Moreover, almost all in vitro experiments have focused solely on the c-MYC oncogene because of its extensive role in a wide variety of tumors. It is therefore still unknown whether dierent MYC members activate dierent or same genes.
We aimed at identifying genes involved in c-MYC or N-MYC induced tumors in humans. Our approach was to identify genes that are induced in several dierent MYC induced tumors in humans. Among these genes we expect to ®nd direct targets of the MYC protein as well as downstream eectors. In order to identify such genes, we generated expression pro®les of several human B-cell lymphomas and neuronal-like tumors by hybridizing labeled cDNA on a DNA array membrane (Clontech) enabling us to monitor the expression level of about 1200 genes. We searched for those genes that were over-expressed in MYC induced B-cell lymphomas and also in MYC induced neuronlike tumors. Furthermore, we examined whether the genes that were over-expressed in the human tumors were also over-expressed in tumors derived from transgenic mice. In this method, we have identi®ed several genes that are over-expressed in both types of MYC induced human tumors, of which some are also over-expressed in the Myc induced tumors from mice. Finally, we searched genomic databases to ®nd out which of the identi®ed genes also harbor a MYC binding motive in their promoter suggesting that they may be direct targets of the MYC oncogenes.
Results
In order to identify genes that are involved in c-MYC and N-MYC oncogenesis in human tumors, we compared the gene expression pro®les of various tumors. The tumors that were chosen for this study are those that are considered as the hallmark of c-MYC and N-MYC induced tumors in humans. Thus, we analysed the expression pro®les of two cell lines derived from dierent Burkitt's lymphomas (BL), where due to a speci®c translocation c-MYC is active (see Table 1a for human cell lines). A high level of c-MYC RNA was previously determined for both Raji and Ramos cell lines by others and by us (Wiman et al., 1984; Ben-Yosef et al., 1998 ) and a high c-MYC protein level was shown in Raji cell line (Ben-Yosef et al., 1998) . In addition, we have previously analysed the expression pro®le of two neuroblastoma (NB) cell lines, where an N-MYC ampli®cation has been shown and also of one cell line derived from a neuroepithelyoma (NE) where a c-MYC ampli®cation has been reported (see Table 1a for human cell lines). A high c-MYC RNA level was shown in SK-N-MC cell line (BenYosef et al., 1998) and a high N-MYC RNA level was shown in NHB and Kelly cell lines (Ben-Yosef et al., 1998) . As a control for the genes expressed in the BLs, we analysed expression pro®les of two non-BL cell lines and in the case of the NBs, the control cell line was a NE where neither c-MYC nor N-MYC are ampli®ed. In order to expand the scope of our experiment and to verify the results, we also compared the results of the analysis of the human tumors to the expression pro®les of cell lines derived from tumors of transgenic mice where causality of the tumors is more evident (see Table 1b ). The human c-MYC transgene was previously shown by us to be expressed in 8MA1A and M1101 cell lines (Ben-Porath et al., 1999) . In addition, we compared the results to the expression pro®le of rat1 cells expressing the MYC-ER chimeric protein before and after induction of c-MYC (see Table 1b ).
Gene expression pro®les were constructed by hybridizing labeled cDNA from the human tumor cell lines onto the Atlas Human 1.2 I DNA array (Clontech). These arrays harbor almost 1200 known genes ± among them 110 oncogenes and tumor suppressor genes, 58 cell cycle regulators and 69 apoptosis related genes (for a complete list see: http://www.clontech.com/ atlas/genelists/index/html). The arrays were analysed using Array Vision DNA chip analysis software. For each gene on the array, local background was subtracted. In order to compare dierent hybridized experiments the results were normalized by dividing the value of each gene by the average signal of all the genes on the array (a more comprehensive description of the analysis is available in the Materials and methods section).
We ®rst compared the gene expression pro®les between dierent tumors (such as BL versus non-BL) and between cells that express dierent levels of c-MYC (rat1 cells where c-MYC is activated versus control cells) (Figure 1 ). Using scattered plot presentation, it is evident that the variance between the pro®les of the dierent tumors is large (Figure 1a ) while the variance between the pro®les of the MYC-ER cell lines is small (Figure 1b) . Such an analysis suggests that the variance in the human tumors may be due to the neoplastic nature of the dierent tumors and not only due to MYC activation. Such large variance may complicate the isolation of genes over-expressed in a single tumor. We therefore looked for the common characteristics of dierent MYC induced tumors compared to the controls. The rationale is that if we ®nd genes that are over-expressed in several dierent BL lines and in MYC induced NBs, we reduce the prevalence of non-speci®c genes and implicate that the identi®ed genes may be important players in many types of MYC-induced tumors.
In order to ®nd the common characteristics of the expression pro®les of the dierent MYC induced tumors ± we ®rst compared each tumor type to its control. More speci®cally, we compared the BL cell lines Raji and Ramos to the non-BL cell lines BJAB and Farage. We also compared the N-MYC NBs Kelly and NHB and the c-MYC tumor SK-N-MC to the control neuronal-like tumor SHEP. Over-expressed genes were selected according to the scheme presented in Figure 2 . (A more comprehensive analysis of the pair wise comparisons that formulate Figure 2 is presented in our web site: http:// www.ls.huji.ac.il/*nissimb/oncogene1.html). We chose genes that were either up regulated in both BL cell lines compared to at least one non-BL cell line or genes that were up regulated in one BL cell line compared to both control lines. In the case of the neuronal-like tumors, because c-MYC and N-MYC may have unique targets as well as mutual ones, we selected genes that were either high in both N-MYC NBs compared to the control or in the c-MYC tumor compared to the control cell line. Following this scheme, 68 genes were up regulated by at least twofolds in the BLs versus the control cell line and 63 genes were induced in the MYC neuronal-like tumors versus the control. Among these two groups of genes, 12 were present in both groups and therefore may be candidate genes that are involved in MYC oncogenesis. The probability that such an overlap will occur in random is less than 0.01%. This low probability means that the criteria for choosing the genes that are induced in each tumor type were not chosen by random. To calculate this probability, we used the following equation:
When A: the number of genes chosen in experiment 1; B: number of genes chosen in experiment 2; N: number of genes in the array; k: number of common genes between A and B.
In order to reinforce the assumption that these 12 genes are actually involved in c-MYC tumorigenesis, we checked their expression pro®les in tumor cell lines derived from transgenic mice and in rat1 cells expressing the MYC-ER chimeric construct. Gene expression pro®les were constructed for the cell lines described in Table 1b by hybridizing cDNA from these Figure 3 . Most of the genes that were over-expressed in human MYC induced tumors were also induced in mouse c-MYC induced tumors. Also notable is that the 12 genes can be divided into two groups: One group contains genes that are up regulated in most of the c-or N-MYC tumors (CDC25B: cell division cycle 25B; TSC2: tuberous sclerosis 2; XRCC1: X-ray repair complementing detective repair in Chinese hamster cells 1; SMARCA4: SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4: E2F1: E2F transcription factor 1; NUCB: nucleobindin 1; PLK1: polo (Drosophila)-like kinase; RXRB: retinoid X receptor, beta; and NRGN: neurogranin), while the second group consists of genes that are up regulated in c-MYC tumors but not in N-MYC tumors (ERBB3: v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3; and IL2RA: interleukin 2 receptor, alpha).
Since the level of expression of some of the genes is very low, analysing the comparison by showing the ratio alone is not a robust description. Thus, we also show in Table 2 the values of the signals of the dierent dots and the dierence between the expression in human and mouse MYC tumors versus non-MYC tumors. As shown, for some of the genes the dierence is more signi®cant (e.g. TSC2 and SMARCA4) than in others (e.g. XRCC1 and RXRB).
The genes identi®ed are favorable candidates to be involved in MYC oncogenesis in humans. Some of these genes may well be transcriptional targets of the MYC oncogenes whether direct or indirect. In order to examine whether any of the selected genes may be a potential direct target of c-MYC, we scanned the promoter regions of these genes for the presence Figure 4a , we scanned, where sequence was available, 2 kb upstream of the promoter and 2 kb downstream. Taking into account the proximity of the elements to the promoter, the location of the elements that are downstream to the promoter (intron, 5'UTR or coding sequences) and the number of elements in the scanned region, we ordered the genes according to the plausibility that they are indeed regulated by MYC proteins. Based on the sequence, it seems that E2F1, TSC2, NRGN, NUCB and RXRB may well be potential targets of the MYC oncogenes. We tested the actual binding capability of both nuclear extract and recombinant c-MYC/MAX complex to sequences derived from Eboxes of the two best candidates namely E2F1 and TSC2 genes. The Electrophoretic mobility shift assay (EMSA) results of these binding assays are presented in Figure 4b . As shown, the DNA elements in both genes actively bind a protein in a nuclear extract isolated from the MycER cells and also bind to the Myc-Max complex of recombinant proteins. There is some binding to Max homodimer as was observed before (Amati et al., 1992) .
In order to validate the cDNA micro-array results for these two genes, we performed an RT ± PCR experiment using primers speci®c to E2F1 and TSC2 genes. As shown in Figure 5 both E2F1 and TSC2 are over-expressed in MYC induced tumors though E2F1 shows a more pronounced eect.
None of the genes we identi®ed were previously shown to be over-expressed in vitro in the MYC-ER cell system. We therefore wanted to see if some of the previously identi®ed genes were over-expressed in the MYC induced tumors we tested but to a lesser extent. Out of 22 genes that were suggested to be activated by Myc (list compiled from Grandori and Eisenman, 1997; Facchini and Penn, 1998; Dang, 1999) , only 13 were present in the Atlas Human 1.2 I membrane. Out of the 13 genes only two genes (aprothymosin and RCL) were expressed in a detectable signal by our hybridization analysis (results not shown). a-prothymosin was indeed over-expressed in some of the MYC induced tumors, mainly in one N-MYC NB cell line where its levels increased by a factor of about 6 and in the BLs by a factor of 1.2 ± 1.8. In addition, RCL was over-expressed by a factor of 1.8 in one BL (Raji) (results not shown). In contrast, RCL was down regulated in all MYC neuronal-like tumors by a factor of 2 ± 5 and by a factor of about 1.4 in the other BL (Ramos). Taken together, these results raise the possibility that genes that are identi®ed in an in vitro system as targets are not necessarily the major targets in human tumors and do not play a major role in MYC induced oncogenesis. SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4; NUCB: nucleobindin 1; E2F1: E2F transcription factor 1; PLK1: polo (Drosophila)-like kinase; RXRB: retinoid X receptor, beta; NRGN: neurogranin (protein kinase C substrate, RC3); ERBB3: v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3; IL2RA: interleukin 2 receptor, alpha Ratio and dierence of Kelly, NHB and SK-NMC were calculated in relation to SH-EP. Ratio and dierence of Raji and Ramos were calculated in relation to Farage. Ratio and dierence of 8MA1A and M1101 were calculated in relation to SH1.1. Note that only nine out of 12 genes were present in the mouse membrane
Discussion
MYC genes play a major role in a wide variety of human malignancies (Nesbit et al., 1999) . Although MYC genes have been under extensive study in the last two decades, the mechanism by which they induce oncogenesis is still enigmatic. MYC proteins are transcription factors that bind a speci®c E-box when heterodimerized with another protein, MAX (Blackwell et al., 1990; Prendergast and Zi, 1992) . Therefore, in order to unfold the mystery of MYC induced oncogenesis, it is necessary to identify and characterize its genetic targets and downstream eectors. Although various genes have been proposed as targets for MYC proteins, especially c-MYC, they do not, as yet, provide us with enough information about MYC- induced oncogenesis (Grandori and Eisenman, 1997; Facchini and Penn, 1998; Dang, 1999) . Moreover, most proposed target genes were identi®ed in vitro mainly by using the hormone inducible form of MYC (MYC-ER) in rodent cells, and, in most cases, their relevance to MYC induced tumorigenesis in humans remains inconclusive.
In order to ®nd genes that play a role in MYC oncogenesis, we think that it is necessary to analyse human tumors. In this study we set out to ®nd the common dierences between various MYC-induced tumors to other tumors, not induced by MYC. When comparing two BL to two non-BL, 68 out of 1200 genes were over-expressed in the MYC induced BLs. In addition, 63 out of 1200 genes were over-expressed in N-MYC induced NB or in a c-MYC induced NE in comparison to the control tumor where neither N-MYC nor c-MYC were ampli®ed. Twelve genes were over-expressed in both types of MYC induced tumors. The probability that such an overlap will occur in random is less than 0.01%. At least eight out of these genes are directly involved in a cell cycle regulation (CDC25B, TSC2, XRCC1, E2F1, PLK1, RXRB, c-MYC and ERBB3). Even though it is not surprising that c-MYC is over-expressed in the MYC induced BLs and NBs, it is not obvious, as in the case of the BL, the gene is expressed in a constitutive manner resulting in elevated levels of protein but not necessarily elevated levels of transcript. In addition, it is important to note that the non-BL lines do not exhibit the common translocation of BL but the actual activity of all MYC or MAX proteins in these tumors is unknown. This allows a plausible explanation to the fact that some of the 12 genes detected by our scan are not low in both non-BLs (see Figure 3 , Ram/BJ and Raj/BJ).
When comparing expression pro®les, it is important to analyse the dierence in the expression level in addition to the ratio between them. This is especially important when measuring genes expressed in low abundance. We therefore calculated the dierences between the expression pro®les of the 12 genes selected before ( Table 2 ). The dierence magnitude emphasizes that some genes (e.g. TSC2, SMARCA4 and CDC25B) are over expressed in a wider spectrum than others (e.g. XRCC1 and RXRB). Taking the two methods of analysis together, it is possible to divide the 12 genes into two groups; one that is composed of genes activated both by N-MYC and c-MYC (CDC25B, TSC2, XRCC1, SMARCA4, E2F1, NUCB, PLK1, RXRB and NRGN) and the second of genes activated by c-MYC alone (cERBB3 and IL2RA). This raises the possibility that c-MYC and N-MYC though sharing some target genes also regulate several genes dierentially. This ®nding is in accordance with previous analysis of the expression level of a few targets of c-MYC in BLs and NBs (Ben-Yosef et al., 1998) . Even though it has been shown that when c-MYC is replaced by N-MYC mice develop normally and do not have any evident defect (Malynn et al., 2000) , it is possible that in vivo, when expressed in dierent tissues c-MYC and N-MYC cooperate with dierent regulators to activate a dierent set of genes.
In order to ascertain whether MYC induced carcinogenesis has common characteristics in human and mice, we examined the expression level of the 12 genes over-expressed in the human tumor, this time in mouse tumors. Cell lines derived from two MMTV/cMyc and one MMTV/v-Ha-Ras transgenic mice were analysed. Due to dierences in the human and mouse cDNA arrays, it was possible to test the expression of nine genes only. Most of the genes (CDC25B, TSC2, XRCC1, SMARCA4, and NUCB) were up regulated in at least one c-MYC-induced tumor compared to the Ha-Ras induced tumor (see Figure 3) . Even though it was previously shown that the mouse cell lines express the human c-MYC transgene (Ben-Porath et al., 1999) we could not show this in the clontech ®lters. In the Atlas system, the human c-MYC transgene is not reverse transcribed when using the kit appropriate for murine genes. This data suggests that while many similarities exist between MYC-induced oncogenesis in human and mouse, some dierences may exist.
We next determined if the genes that are overexpressed in MYC induced human tumors were also elevated in vitro. We obtained expression pro®les of rat1 cells expressing the chimeric protein MYC-ER before and after activation of c-MYC. Only ®ve out of the 12 genes are manifested in the Rat array. Moreover, four out of the ®ve genes were not expressed at all in the rat1 cells while one gene ± CDC25B ± was down regulated in this assay. This raises again the question whether target genes identi®ed in vitro are also involved in in vivo malignant processes. This question remains, as yet, unresolved.
In our study, we searched for genes that participate in MYC induced oncogenesis. Such genes may be genetic targets of the MYC proteins, whether direct or indirect. In order to assess whether any of the 12 genes identi®ed could be a direct target for MYC activation, we mined genomic databases in search of the regulatory regions of these genes. De®ning regulatory sequences in mammals may be dicult but it is accepted that in most known target genes, the c-MYC-binding site is near the promoter. We therefore scanned the databases for sequences spanning 2 kb upstream to 2 kb downstream to the start site of transcription. Genomic sequences were available for 10 out of the 12 genes. Six out of the 10 genes nest at least one E-box in the 4 kb spanning the promoter and may, therefore, be direct targets of the MYC proteins (Figure 4a) . Moreover, taking into account the number of sites and their location, three genes, namely E2F1, RXRB and TSC2 harbor at least two binding sites with at least one located within 1 kb from the start of transcription. As shown in Figure  4b , both nuclear extract and recombinant c-MYC/ MAX complexes bind sequences derived from the Eboxes present in the E2F1 and TSC2 genes. We further tested by RT ± PCR analysis expression of both E2F1 and TSC2 in the tumor cells, both genes are shown to be over-expressed in the MYC induced tumors by RT ± PCR (Figure 5 ), nevertheless, E2F1 shows a more pronounced eect.
Interestingly, E2F1 has been suggested as a regulator of c-MYC expression (Oswald et al., 1994) . Furthermore, it has been previously suggested that other E2F family members may be regulated by MYC activity Leone et al., 2000) . This could suggest a possible auto-regulatory loop between E2F genes and MYC. These results support the possibility that some of the genes identi®ed in our screen may well be direct targets of MYC proteins. Nonetheless, in order to prove this assumption, further studies are necessary.
TSC2 (tuberin) was also suggested to be involved in tumor formation. It is mutated in the hereditary tuberous sclerosis disease, which is characterized by development of benign hemartomas (Gomez et al., 1999) . In addition, mice heterozygous for the gene develop various adenomas and other tumors (Onda et al., 1999) . Tuberin was suggested to function as a GTPase-activating protein and was implied to be involved in cell-cycle regulation (Wienecke et al., 1995; Xiao, 1997; Soucek et al., 1998) . Interestingly, mice which are homozygous to null mutation in TSC, die at embryonic day 9 ± 12.5, similarly to mice mutated in either c-Myc or N-Myc (Charron et al., 1992; Stanton et al., 1992; Onda et al., 1999) .
Most known genetic targets for MYC activation were isolated in in vitro systems, mainly in rodent cells. In our experiment, none of the previously described targets met all the criteria we required. We nevertheless wanted to assess the expression level of these genes in the human tumors analysed. Only two genes out of 22 (list compiled from Grandori and Eisenman, 1997; Facchini and Penn, 1998; Dang, 1999) were present in the Atlas Human 1.2 I membrane and also expressed in detectable levels. These were a-prothymosin and RCL. The expression of RCL was low in N-and c-MYC induced neuronal-like tumors and was slightly elevated in BLs. a-prothymosin was over-expressed in one NB, and slightly over-expressed in BLs. Eleven genes were not expressed in a detectable level at all and nine were not present in the arrays. These results suggest that even though MYC may regulate some genes in normal tissue, they do not necessarily play a major role in a fully developed MYC induced tumor. Furthermore, the results suggest that many known targets of the MYC genes are expressed in very low level in tumors and their role in the malignant transformation remains unclear.
In conclusion, we present here a new, in vivo, method to search for genes involved in MYC tumorigenesis. Since the malignant process is accompanied with many genomic changes, causing alteration in the expression level of many genes, dierent tumors, or maybe even dierent cells in the same tumor, may have many dierences between them when comparing their expression pro®les. We therefore believe that it is necessary to perform many comparisons between dierent types of tumors and look for the common changes. Characterizing the common dierences between dierent MYC induced tumors and control cell lines, allows us to concentrate on the genes that are aected by the erroneous expression of MYC rather than tissue speci®c genes that are important for tumor development. Nevertheless, we cannot rule out the possibility that some of the genes we identi®ed are due to tumor development and not due to MYC expression. We suggest 12 new genes as players in MYC induced tumorigenesis and provide evidence that two of them may be direct targets of the MYC oncoproteins.
Materials and methods

Cell lines and media
A list of the cell lines used in this study appears in Table 1 . Human lymphoma cell lines were grown in suspension in RPMI-1640 medium supplemented with 10% fetal calf serum. Human NB and NE cell lines were grown in RPMI-1640 medium supplemented with 15% fetal calf serum. Rat1 cells and the cell lines derived from transgenic mice tumors were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum. All media were supplemented with 50 units/ml of penicillin G, 50 mg/ml of streptomycin and 4 mM L-glutamine. For MYC-ER induction experiments Rat1 cells were grown to con¯uency, serum-starved for 3 days after which 200 nM 4-hydroxytamoxifen (4-OHT) (Sigma Biosciences) was added to the medium.
RNA isolation, probe preparation and hybridization
Total RNA was extracted using Atlas TM Pure Total RNA Kit (Clontech). cDNA probes were synthesized using the Atlas TM Pure Total RNA Kit (Clontech) and Atlas TM Human 1.2 array, Atlas TM Mouse 1.2 array or the Atlas TM Rat 1.2 array (Clontech). Radioactive labeling of the probe was performed using a-32 P dATP (3000 Ci/mmol, 10 mCi/ml) (Amersham). Hybridization was performed as described in Atlas TM cDNA Expression Arrays user manual (Clontech). Arrays were exposed to a BioMax MS X-ray ®lm (Kodak) in 7708C.
Array analysis
Exposed ®lm of similar density were scanned in a¯atbed scanner and analysed using Array Vision TM (Imaging Research) and Atlas Image 1.0 (Clontech). Both analyses gave similar results and shown are the results of the analysis with the Array Vision TM software. Local background was subtracted from each signal. The analysed arrays were also screened manually to determine which signals are in the dynamic range and readings outside the dynamic range were omitted from the analysis. Nevertheless, when the signal for a speci®c gene was outside the dynamic range in one array and inside the range in another, the value that was outside the range was¯oored by a value just inside this dynamic range. This procedure enables us to calculate a ratio between the two arrays, which is an underestimation of the real ratio between the signals. The results were exported to Excel for further analysis. In order to normalize between dierent arrays, each signal was divided by the average signal of each array. All comparisons are pair wise comparisons. In Figure  3 , when two cell lines are compared with one cell line, the
